VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024

Quality Of Top Five Financings Bodes Well

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.

Internet, business, Technology and network concept. Venture capital. Investor capital.
Q4 VC funding fell from Q3, but smaller deals rebounded • Source: Shutterstock

The slowdown in financings across the biopharmaceutical spectrum hit private and public companies alike in 2023 and the latest venture capital fundraising data from Evaluate indicate that last year did not end on a high note. However, the numbers mostly show the industry holding steady as it braces for a potential upswing in 2024 based on signs that financial market conditions may be easing.

Key Takeaways

  • Venture capital fundraising by biopharma companies declined from $4.28bn in Q3 to $3.71bn in Q4, according to Evaluate.

Evaluate tallied $3.71bn in venture capital raised globally by 86 drug developers during the fourth quarter, down from $4.28bn raised...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.